Upstream Bio, Inc.

NASDAQ:UPB

Biotechnology

Healthcare
$2.08 +1.63%

+$0.10 today

Market cap
$114.01M
Beta
1.11
P/E (TTM)
-2.2
EPS (TTM)
-$2.89
52W Low $5.85High $33.68

Volume 1.24M

Average 0.66M

UPB Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

Upstream Bio, Inc.NASDAQ: UPB

Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026

Capital expenditures outflow grows to $0

Q1 FY2026 capital expenditures was $0, compared with $0 a year earlier. Trailing-twelve-month capital expenditures was -$47K. Over 3 fiscal years it compounded at +26.2% a year.

Context

  • Capital expenditures amounted to 5.8% of revenue in FY2025, down 15.8 pp from a year earlier.
  • Capital expenditures grew in size in 2 of the last 3 fiscal years.

What to watch

Whether quarterly capital expenditures holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$11.75K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0+100.0% QoQ
Last fiscal yearDec 2025
-$165K-67.7% YoY
LTMMar 2026
-$47K-90.8% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-67.7%——
3-year CAGR+26.2%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(165K) USD
Year-over-year change
+67.7%

Capital Expenditures vs competitors

How UPB compares with its peers on the latest reported figures

  • Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -90.8% is the 7th highest of 8, against a peer median of -37.6%.
  • Capital expenditures amounts to 1.4% of revenue for UPB, versus a peer median of 0.4%.
UPB Competitors
Capital Expenditures for UPB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVAXNovavax, Inc.LTM Mar 2026$5.61M USD-37.6%-60.9%0.9%
WVEWave Life Sciences Ltd.LTM Mar 2026$981.99K USD+43.1%-19.2%1.4%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$473K USD-88.2%-53.7%0.7%
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$187K USD—-6.0%0.1%
AMLXAmylyx Pharmaceuticals, Inc.LTM Sep 2026$141K USD+95.8%-62.1%—
PHVSPharvaris N.V.LTM Sep 2026€81.4K EUR-74.9%+9.8%—
UPBUpstream Bio, Inc.LTM Mar 2026$47K USD-90.8%+26.2%1.4%
ZBIOZenas BioPharma, Inc.LTM Mar 2026$2K USD-98.4%-79.8%—
SYRESpyre Therapeutics, Inc.LTM Sep 2026$0 USD——0.0%
RLAYRelay Therapeutics, Inc.LTM Jun 2026$0 USD+100.0%-64.4%0.0%
Peer median (excluding UPB) —-37.6%-57.3%0.4%

Competitors are the stored peer set for UPB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(23.87M)(20.54M)(62.81M)(143.44M)
Depreciation & Amortization7K60K89K(1.31M)
Deferred Income Tax0000
Stock-Based Compensation1.28M3.43M6M10.33M
Change in Working Capital3.41M(4.31M)1.87M589K
Accounts Receivables(412K)314K(515K)(55K)
Inventory0000
Accounts Payables462K1.28M2.02M(1.28M)
Other Working Capital3.36M(5.9M)371K1.93M
Other Non-Cash Items149K(16.57M)(4.33M)561K
Operating Cash Flow(19.02M)(37.93M)(59.17M)(133.28M)
Capital Expenditures(82K)(144K)(511K)(165K)
Acquisitions (Net)0000
Purchases of Investments0(128.99M)(290.61M)(385.88M)
Sales of Investments046.29M231.64M292.56M
Other Investing Activities0000
Investing Cash Flow(82K)(82.84M)(59.49M)(93.48M)
Debt Repayment0000
Common Stock Issued9.96M129.55M272.72M2.44M
Common Stock Repurchased0000
Dividends Paid0000
Other Financing Activities(37K)118K(3.74M)0
Financing Cash Flow9.96M129.55M418.91M2.44M
Effect of Forex Changes0000
Net Change in Cash(9.14M)8.78M300.25M(224.31M)
Free Cash Flow(19.1M)(38.07M)(59.68M)(133.28M)

Upstream Bio, Inc.

NASDAQ:UPB

Intrinsic Alpha fair value

Locked

Current Price

$2.08

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.